Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Yicura BioMed Holds Pre-Launch Preparation Meeting and IDMC Kick-off Meeting for ICVAX-201 Clinical Project

ICVAX® Phase II Clinical Study Enters Key Preparation Stage

BEIJING, CHINA – Media OutReach Newswire – 19 November 2026 – Yicura BioMed held the Pre-launch Preparation Meeting and the Independent Data Monitoring Committee ("IDMC") Kick-off Meeting for the ICVAX-201 clinical project in Beijing today.

ICVAX® is a therapeutic HIV DNA vaccine candidate developed based on Yicura BioMed's PD-1-enhanced DNA vaccine platform. The meeting focused on discussions regarding the implementation preparations, study protocol, and independent data monitoring arrangements for ICVAX® Phase II clinical trial, laying the foundation for the subsequent smooth progress of the project.

ICVAX-201 is a National Medical Products Administration ("NMPA") approved registrational Phase II clinical trial, which is a cross-border, multi-centre, randomized, double-blind, placebo-controlled clinical trial involving a total of 5 clinical trial centres in Chinese mainland and Hong Kong, with Prof. Fujie ZHANG of Beijing Ditan Hospital, Capital Medical University, who is also the Leader of the AIDS Clinical Expert Working Group of the National Health Commission, serving as the Principal Investigator. The primary objective of the trial is to explore the immune protection mechanism of ICVAX®, and the secondary objectives are to evaluate its efficacy in suppressing HIV-1 RNA viral load, as well as the safety of its combination with antiretroviral therapy ("ART") in controlling HIV-1 infection following analytical treatment interruption ("ATI"). Participating centres in Chinese mainland include Beijing Ditan Hospital, Capital Medical University; Beijing Youan Hospital, Capital Medical University; Guangzhou Eighth People's Hospital; and The Third People's Hospital of Shenzhen. The participating centre in Hong Kong is the Phase I Clinical Trial Centre of The Chinese University of Hong Kong. The centres will collaborate to advance the study and explore the potential of ICVAX® in the field of functional cure for HIV.

Dr. Xia JIN, Co-Founder and Chief Executive Officer of Yicura BioMed, stated that the completion of NMPA approved registrational Phase I clinical trial of ICVAX® and its entry into the preparation stage for the Phase II clinical trial marks an important step forward in the project's clinical development. Yicura BioMed will work closely with all partners, strictly execute the study protocol, implement quality management requirements, and promote the standardized and orderly progress of the Phase II clinical study.

Professor Zhiwei CHEN, Tenured Chair Professor of Immunology and Immunotherapy, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Suen Chi-Sun Professor in Clinical Science, who is also as the inventor of the PD-1-enhanced DNA vaccine technology and the Principal Scientific Advisor of Yicura BioMed, introduced the R&D background of ICVAX®. Focusing on its technical foundation, mechanism of action, and R&D strategy, he elaborated on the scientific basis for conducting subsequent clinical studies of ICVAX®.

Professor Hongzhou LU of The Third People's Hospital of Shenzhen, the Principal Investigator of the ICVAX® Phase I clinical trial, presented the results of the Phase I clinical trial and the progress of the Phase I extension investigator-initiated trial ("IIT"). In the first-in-human Phase I clinical trial of ICVAX®, all 45 subjects completed follow-up, and the results demonstrated promising safety and immunogenicity. In the subsequent treatment interruption observation, after receiving two rounds of booster in the enrolled 10 subjects, the proportion achieving sustained virological suppression after treatment interruption increased from 10% (1/10) to nearly 30% (2/7) in the second stage. Of the 2 subjects enrolled in the third stage, 1 subject maintained sustained virological suppression for more than 70 weeks (17.5 months) without restarting ART.

Professor Fujie ZHANG, Principal Investigator of the ICVAX® Phase II clinical trial, introduced the Phase II clinical study protocol. Participating experts conducted in-depth exchanges on the study design, implementation arrangements, and key issues in the study.

The IDMC Kick-Off meeting was held concurrently during the conference, during which the committee members and working protocol were introduced, and a letter of appointment presentation ceremony was held. In compliance with the protocol, the IDMC will independently review the clinical trial progress and relevant data and provide professional recommendations on the protection of subject safety and the implementation of the study.

Hashtag: #Yicura #醫克生物



The issuer is solely responsible for the content of this announcement.

About Yicura BioMed (formerly known as Immuno Cure)

Yicura BioMed is a clinical-stage biotechnology group based in Hong Kong Science Park, focusing on the research and development of immunotherapies for cancers, inflammations, and infectious diseases based on its patented PD-1-enhanced DNA vaccine and anti-Δ42PD1 antibody platforms.

To learn more about Yicura, please visit:

News from Asia

Allianz: Reported AI losses understate the true risk and are only the tip of the iceberg

Allianz Commercial analysis highlights emerging and interconnected risks and claims scenarios related to global AI adoption in businesses.

APEC Gathering Fulfills Shenzhen Vendor’s 25-Year Global Friendship Wish

SHENZHEN, CHINA — Media OutReach Newswire – 19 November 2026 – Amid the ongoing 33rd APEC Economic Leaders' Meeting hosted in Shenzhen, a heartwarming story of cross-border friendship has emerged ...

Viet Nam Takes Global Lead in New Climate-Smart Agrifood Partnership Launched at COP31

ANTALYA, TURKEY– Media OutReach Newswire – 19 November 2026 – Viet Nam has taken a significant step in advancing its role in international climate and food systems diplomacy with the launch of a n...

SACOFA Fortifies Connectivity Partnership to Advance Kenyalang Smart City, witnessed by The Premier of Sarawak

SARAWAK, MALAYSIA – Media OutReach Newswire – 19 November 2026 – SACOFA Sdn Bhd (SACOFA) is strengthening its role as the primary backhaul connectivity and telecommunications infrastructure partne...

Dual Engines Driving the Green Transition! WGO Hosts the "Sustainable Finance Award" and "Sustainable Enterprise Award" to Honour Cross-Sector Pioneers

HONG KONG SAR – Media OutReach Newswire – 19 November 2026 – The World Green Organisation (WGO) proudly hosted the presentation ceremony for the "Sustainable Finance Award" and the "Sustainable En...

From the South China Sea to the Aegean: Nansha Seeks Closer Cooperation with Greece in Coastal Sports and Tourism

GUANGZHOU, CHINA – Media OutReach Newswire – 19 November 2026 – During the China-Greece Sports and Cultural Exchange Week held in Athens on November 3, a delegation from Nansha District, Guangzhou...

Yicura BioMed Holds Pre-Launch Preparation Meeting and IDMC Kick-off Meeting for ICVAX-201 Clinical Project

ICVAX® Phase II Clinical Study Enters Key Preparation StageBEIJING, CHINA – Media OutReach Newswire – 19 November 2026 – Yicura BioMed held the Pre-launch Preparation Meeting and the Independent D...

Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI

AACHEN, GERMANY – Newsaktuell – 19 November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, star...

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach Newswire – 19 November 2026 –Thi...

AXS and PayerMax Advance Omnichannel Payment Acceptance for Merchants

SINGAPORE – Media OutReach Newswire – 19 November 2026 – AXS Pte Ltd (AXS), a leading bill management and payment acceptance solutions provider, and PayerMax, a global payment solutions provider, ...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...

Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty

The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...